- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 10:35 | GSK's Hal Barron heralds their second positive PhIII for crucial anti-BCMA therapy, pointing to a push for quick OKs in a crowded field | ||
| Do | Biotech leaders rally behind Chinese scientists in US, calls for 'measured' policies in wake of purges | ||
| Do | Amgen, Allergan biosimilar of Roche's blockbuster Rituxan clears another US pivotal study | ||
| Do | BeiGene and Mustang nail down special FDA status for top drugs; Roche bags added coverage for Hemlibra | ||
| Do | Trump administration revives bid to get drug list prices on TV ads | ||
| Do | Get as much Spravato as you can, Trump orders VA while suggesting J&J should offer it to veterans for free | ||
| Do | An emboldened AstraZeneca splurges $95M on a priority review voucher. Where do they need the FDA to hustle up? | ||
| Do | Versant-backed Chinook gets a $65M launch round for its discovery quest in a resurgent kidney field | ||
| Do | Sir Andrew Dillon, NICE's first - and only - chief executive to step down next year | ||
| Do | Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK for long-acting regimen | ||
| Do | Prisoner #87850-053 does not get to add drug developer to his list of credits | ||
| Do | Finch grabs a $53M round designed to take their 'breakthrough' microbiome treatment through a potentially pivotal trial | ||
| Do | Vienna-based vaccine developer Themis signs pact with Merck for 'blockbuster indication' | ||
| Mi | SEC calls out little TherapeuticsMD for selective disclosure of FDA updates following CRL | ||
| Mi | GSK submits its first application for daprodustat in Japan; Two drugmakers part with $15M to avoid opioid trial | ||
| Mi | MDMA, now in Phase III, shows promise as a PTSD treatment | ||
| Mi | Pfizer is making a $500M statement today: Here's how you become a lead player in the booming gene therapy sector | ||
| Mi | MHRA to land a new interim chief executive ahead of Brexit | ||
| Mi | Video: Putting the AI in R&D - with Badhri Srinivasan, Tony Wood, Rosana Kapeller, Hugo Ceulemans, Saurabh Saha and Shoibal Datta | ||
| Mi | Cowen, Perceptive lead $79.5M Series B for 'standout' biotech shepherding oncolytic virus to clinic | ||
| Mi | Futility analysis augurs defeat in pivotal trial testing of NuCana's lead drug in metastatic pancreatic cancer | ||
| Mi | AstraZeneca's Imfinzi/treme combo strikes out - again - in lung cancer. Is it time for last rites? | ||
| Di | Webinar: Real World Endpoints - the brave new world coming in building franchise therapies | ||
| Di | Pfizer Foundation offers $2M in grants to NGOs tackling antimicrobial resistance; Biogen, Invitae join forces to develop faster SMA diagnostic | ||
| Di | FDA decision on Vertex's CF triple will come just ahead of planned CEO shakeup |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
